(NYSEMKT: CLDI) Calidi Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.25%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 66.22%.
Calidi Biotherapeutics's earnings in 2026 is -$25,010,000.On average, 3 Wall Street analysts forecast CLDI's earnings for 2026 to be -$6,854,905, with the lowest CLDI earnings forecast at -$6,585,991, and the highest CLDI earnings forecast at -$7,056,470. On average, 3 Wall Street analysts forecast CLDI's earnings for 2027 to be -$5,909,359, with the lowest CLDI earnings forecast at -$5,677,620, and the highest CLDI earnings forecast at -$6,083,164.
In 2028, CLDI is forecast to generate -$5,761,625 in earnings, with the lowest earnings forecast at -$5,535,679 and the highest earnings forecast at -$5,931,085.